

# **Supporting information**

## **A tailor made deazaflavin-mediated recycling system for artificial nicotinamide cofactor biomimetics**

*Jeroen Drenth<sup>†‡</sup>, Guang Yang<sup>†‡</sup>, Caroline E. Paul<sup>§</sup> and Marco W. Fraaije<sup>†\*</sup>*

<sup>†</sup>Molecular Enzymology Group, University of Groningen, Nijenborgh 4, 9747AG Groningen,  
The Netherlands

<sup>§</sup>Department of Biotechnology, Delft University of Technology, Van der Maasweg 9, 2629HZ  
Delft, The Netherlands

<sup>‡</sup>These authors contributed equally to this work

<sup>\*</sup>Corresponding author: m.w.fraaije@rug.nl

## Table of contents

QuikChange mutagenic primers used to engineer <i>Tfu</i> -FNO.....	3
Graphs of steady-state kinetic analysis of <i>Tfu</i> -FNO with varying concentrations of NCBs.....	5
Activity screen for different <i>Tfu</i> -FNO mutants with selected NCBs .....	7
Graphs of steady-state kinetic analysis of engineered <i>Tfu</i> -FNO variants with varying concentrations of NCBs .....	10
Activity screen for double mutants with selected NCBs .....	12
pH dependence for NCB reduction by <i>Tfu</i> -FNO .....	13
Steady-state kinetic parameters for selected <i>Tfu</i> -FNO variants toward NADP <sup>+</sup> .....	13

## QuikChange mutagenic primers used to engineer *Tfu*-FNO


**Table S1:** QuikChange mutagenic primers used to engineer *Tfu*-FNO. Abbreviations fw and rv are used to designate the forward and reverse primers, respectively. Primers were designed using the Agilent QuikChange primer design tool ([www.genomics.agilent.com; primerDesignProgram.jsp](http://www.genomics.agilent.com/primerDesignProgram.jsp)).

Mutation		Primer sequence
A87S	fw	tcccacggAACGACACGATCACCACG
	rv	cgtggtgcTGTcggtccgtggaa
V113S	fw	gaaACCCAGCGGGTCGAACAGTCGACGACGATC
	rv	gatcgTCGTCGACTGTTGATCAGGGCCGC
G29F	fw	gcggccCTGATCAAACGTGCCCGAGC
	rv	gctggggggcacgtttGATCAGGGCCGC
G29H	fw	gcggccCTGATCATGCGTGCCCCCAGC
	rv	gctggggggcacGATGATCAGGGCCGC
G29I	fw	gcggccCTGATCAATCGTGCCCCCAGC
	rv	gctggggggcacGATGATCAGGGCCGC
G29L	fw	cgccgcCTGATCTAGCGTGCCCCCAGC
	rv	gctggggggcacGCTAGATCAGGGCCGC
G29M	fw	ccgcggccCTGATCCATCGTGCCCCCAGCA
	rv	tgctggggggcacGATGATCAGGGCCCG
G29N	fw	gcggccCTGATCATTGCGTGCCCCCAGC
	rv	gctggggggcacGAAATGATCAGGGCCGC
G29Q	fw	cgccgcCTGATCCTGCGTGCCCCCAGC
	rv	gctggggggcacGCGAGGATCAGGGCCGC
G29S	fw	ggccCTGATCACTCGTGCCCCCAG
	rv	ctggggggcacGAGTGAATCAGGGCC
G29V	fw	ggccCTGATCAACCCTGCCCCC
	rv	ggggggcacGGTTGATCAGGGCC
G29W	fw	gcggccCTGATCCCACGTGCCAG
	rv	ctggggggcacGTTGGATCAGGGCC
G29Y	fw	gcggccCTGATCATACGTGCCAG
	rv	gctggggggcacGATGATCAGGGCCGC
P89F	fw	cggtaaccGTCAGAAACGCCACGATCACCAC
	rv	gtggtaGATCGTGGCGGTTCTGGACGGTCACCG
P89H	fw	cggtaaccGTCATAACCGCCACGATCACCAC
	rv	gatcgTGGCGGTTCTGGACGGTCACCG
P89I	fw	cggtaaccGTCATAACCGCCACGATCACCAC
	rv	gtggtaGATCGTGGCGGTTATATGGACGGTCACCG
P89L	fw	gtgaccGTCACAGAACCGCCACGAT
	rv	atcgTGGCGGTTCTGGACGGTCAC
P89M	fw	gaccGTCACATAACCGCCACGATCACCACG
	rv	acgtggtaGATCGTGGCGGTTATGTGGACGGTC
P89N	fw	cggtaaccGTCATAACCGCCACGATCACCAC
	rv	gtggtaGATCGTGGCGGTTAATTGGACGGTCACCG
P89Q	fw	gtgaccGTCACAGAACCGCCACGAT
	rv	atcgTGGCGGTTCTGGACGGTCAC
P89S	fw	gaccGTCACAGAACCGCCACGATCA
	rv	tgatcgTGGCGGTTCTGGACGGTC
P89V	fw	accgtcccACACAACGCCACGATCACCAC
	rv	gtggtaGATCGTGGCGGTTGTGGACGGT
P89W	fw	accgtcccACACAACGCCACGATCACCAC
	rv	gtggtaGATCGTGGCGGTTGGTGGACGGT


P89Y            fw     cggtaaccgtccaaataaaccgccacgatcaccac  
                  rv     gtggtgatcggtggcggttattgggacggtcaccg

---

**Graphs of steady-state kinetic analysis of *Tfu*-FNO with varying concentrations of NCBs**




**Figure S1:** The observed initial rates,  $k_{obs}$ , of wild-type *Tfu*-FNO plotted against the concentrations of artificial nicotinamide cofactor biomimetics (NCBs) with apolar groups at position 1 of the nicotinamide. Data in the left column is fitted to the Michaelis-Menten formula and data in the right column is fitted to the Michaelis-Menten formula with substrate inhibition. Data was fitted by non-linear regression, GraphPad Prism v. 6.0 (GraphPad Software Inc., La Jolla, CA, U.S.A.). Data points and error bars represent means and standard deviations of triplicates. EtNA<sup>+</sup>: 1-ethylnicotinamide, ProNA<sup>+</sup>: 1-propylnicotinamide, BNA<sup>+</sup>: 1-benzylnicotinamide.




**Figure S2:** The observed initial rates,  $k_{obs}$ , of wild-type *Tfu*-FNO plotted against the concentrations of artificial nicotinamide cofactor biomimetics (NCBs) with polar groups at position 1 of the nicotinamide. Data in the left column is fitted to the Michaelis-Menten formula and data in the right column is fitted to the Michaelis-Menten formula with substrate inhibition. Data was fitted by non-linear regression, GraphPad Prism v. 6.0 (GraphPad Software Inc., La Jolla, CA, U.S.A.). Data points and error bars represent means and standard deviations of triplicates, respectively. EtOHNA<sup>+</sup>: 1-hydroxyethylnicotinamide, ProNA<sup>+</sup>: 1-hydroxypropylnicotinamide, AmNA<sup>+</sup>: 1-carbamoylethylnicotinamide.


### Activity screen for different *Tfu*-FNO mutants with selected NCBs



**Figure S3:** Activity screen of selected *Tfu*-FNO G29X and P89X variants with polar amino acid side chains toward artificial nicotinamide cofactor biomimetics (NCBs) with polar groups at position 1 of the nicotinamide. Data in the left column and right column are the activity measured with 1 mM NCB and 40 mM NCB, respectively. Data points represent individual  $k_{obs}$  measurements and bars represent the mean value of these two data points. The horizontal dotted line is the mean value of wild-type activity.




**Figure S4:** Activity screen of selected *Tfu*-FNO G29X and P89X variants with apolar amino acid side chains toward artificial nicotinamide cofactor biomimetics (NCBs) with apolar groups at position 1 of the nicotinamide. Data in the left column and right column are the activity measured with 1 mM NCB and 40 mM NCB, respectively. Data points represents individual  $k_{obs}$  measurements and bars represent the mean value of these two data points. The horizontal dotted line is the mean value of wild-type activity.




**Figure S5:** Activity screen of selected *Tfu*-FNO G29X and P89X variants toward the natural NAD(P) precursors nicotinamide ribose (NR) and nicotinamide mononucleotide (NMN). Data points represents individual  $k_{obs}$  measurements and bars represent the mean value of these two data points. The horizontal dotted line is the mean value of wild-type activity.

**Graphs of steady-state kinetic analysis of engineered *Tfu*-FNO variants with varying concentrations of NCBs**




**Figure S6:** The observed initial rates,  $k_{obs}$ , of selected *Tfu*-FNO G29X and P89X variants with polar side chains plotted against the concentrations of artificial nicotinamide cofactor biomimetics (NCBs) with polar groups at position 1 of the nicotinamide. Data in the left column is fitted to the Michaelis-Menten formula with substrate inhibition and data in the right column is fitted to the Michaelis-Menten formula. Data was fitted by non-linear regression, GraphPad Prism v. 6.0 (GraphPad Software Inc., La Jolla, CA, U.S.A.). Data points and error bars represent means and standard deviations of triplicates, respectively. EtOHNA<sup>+</sup>: 1-hydroxyethylnicotinamide, ProNA<sup>+</sup>: 1-hydroxypropylnicotinamide, AmNA<sup>+</sup>: 1-carbamoylethylnicotinamide.




**Figure S7:** The observed initial rates,  $k_{obs}$ , of selected *Tfu*-FNO G29X and P89X variants plotted against the concentrations of artificial nicotinamide cofactor biomimetics (NCBs) with apolar groups at position 1 of the nicotinamide. Data in the left column is fitted to the Michaelis-Menten formula with substrate inhibition and data in the right column is fitted to the Michaelis-Menten. Data was fitted by non-linear regression, GraphPad Prism v. 6.0 (GraphPad Software Inc., La Jolla, CA, U.S.A.). Data points and error bars represent means and standard deviations of triplicates, respectively. EtNA<sup>+</sup>: 1-ethylnicotinamide, ProNA<sup>+</sup>: 1-propylnicotinamide, BNA<sup>+</sup>: 1-benzylnicotinamide.

**Activity screen for double mutants with selected NCBs**



**Figure S8:** Activity screen of selected *Tfu*-FNO G29X/P89X double mutant variants, as well as A87S and V113S, toward the natural NAD(P) precursor nicotinamide ribose (NR) and the polar artificial nicotinamides AmNA<sup>+</sup>, EtOHNA<sup>+</sup> and ProOHNA<sup>+</sup>. Data points represent individual  $k_{obs}$  measurements and bars represent the mean value of these two data points.

### pH dependence for NCB reduction by *Tfu*-FNO



**Figure S9:** pH dependence of NCB-reduction by *Tfu*-FNO.

### Steady-state kinetic parameters for *Tfu*-FNO variants toward selected $\text{NADP}^+$

**Table S2:** Steady-state kinetic parameters for wild-type *Tfu*-FNO and selected *Tfu*-FNO G29X and P89X variants toward selected  $\text{NADP}^+$ . Values are means from 3 independent measurements  $\pm$  standard deviations.

variant	$k_{cat}$ ( $\text{s}^{-1}$ )	$K_m$ ( $\mu\text{M}$ )	$k_{cat}/K_m$ ( $\text{s}^{-1} \text{ M}^{-1}$ )	$(k_{cat}/K_m)_{\text{mutant}} / (k_{cat}/K_m)_{\text{wt}}$
wt	4.9 $\pm$ 0.21	1.1 $\pm$ 0.21	$4.5 \cdot 10^6$ $\pm$ $8.7 \cdot 10^5$	
G29L	0.63 $\pm$ 0.03	$1.2 \cdot 10^3$ $\pm$ 140	522 $\pm$ 65	$1.2 \cdot 10^{-4}$ $\pm$ $2.7 \cdot 10^{-5}$
G29W	2.6 $\pm$ 0.13	697 $\pm$ 109	$3.7 \cdot 10^3$ $\pm$ 612	$8.4 \cdot 10^{-4}$ $\pm$ $2.1 \cdot 10^{-4}$
G29Y	0.17 $\pm$ 0.005	8.2 $\pm$ 0.72	$2.1 \cdot 10^4$ $\pm$ $1.9 \cdot 10^3$	$4.7 \cdot 10^{-3}$ $\pm$ $1.0 \cdot 10^{-3}$
P89H	20 $\pm$ 0.61	14 $\pm$ 1.5	$1.4 \cdot 10^6$ $\pm$ $1.5 \cdot 10^5$	0.3 $\pm$ 0.07
P89L	0.55 $\pm$ 0.02	65 $\pm$ 8.0	$8.4 \cdot 10^3$ $\pm$ $1.1 \cdot 10^3$	$1.9 \cdot 10^{-3}$ $\pm$ $4.4 \cdot 10^{-4}$
P89Y	3.9 $\pm$ 0.16	86 $\pm$ 15	$4.5 \cdot 10^4$ $\pm$ $8.1 \cdot 10^3$	$1.0 \cdot 10^{-2}$ $\pm$ $2.7 \cdot 10^{-3}$